A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. - Related Studies

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

This study has been completed.

Study NCT00034489. Last updated on July 18, 2006. Information provided by Eli Lilly and Company

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Breast Neoplasms

2	More general conditions related to this trial
		Breast Diseases
		Neoplasms
		Neoplasms by Site
		Skin Diseases

3	Interventions listed in this trial
		pemetrexed
		gemcitabine

4	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Folic Acid Antagonists
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

5	Sponsors listed in this trial
		Eli Lilly and Company